Corrigendum: Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP.B

Kasey L. Jackson¹, Robert D. Dayton¹, Benjamin E. Deverman² and Ronald L. Klein¹*

¹ Department of Pharmacology, Toxicology, and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA, USA, ² Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA

Keywords: adeno-associated virus, amyotrophic lateral sclerosis, gene therapy, gene transfer, promoter, synapsin promoter, targeting, TDP-43

A corrigendum on

Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP.B


The following acknowledgments were missing from the original article.

BD was supported by the Hereditary Disease Foundation, the Beckman Institute and the Resource Center for CLARITY, Optogenetics and Vector Engineering, which supports technology development and dissemination at the California Institute of Technology. The AAV-PHP.B plasmid was distributed from the Gradinaru Laboratory at the California Institute of Technology. The authors thank Viviana Gradinaru for her help in providing the AAV-PHP.B plasmid.

The authors apologize for this mistake. This error does not in any way change the scientific conclusions of the article.

Conflict of Interest Statement: BED is listed as an inventor on a patent application related to AAV-PHP.B. KLJ, RDD and RLK have no conflicts of interest to disclose.

Copyright © 2016 Jackson, Dayton, Deverman and Klein. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.